Clinical Trial Details
— Status: Completed
Administrative data
NCT number |
NCT06091592 |
Other study ID # |
DYB-GC-AB-01 |
Secondary ID |
|
Status |
Completed |
Phase |
|
First received |
|
Last updated |
|
Start date |
December 30, 2020 |
Est. completion date |
December 25, 2021 |
Study information
Verified date |
October 2023 |
Source |
Diskapi Yildirim Beyazit Education and Research Hospital |
Contact |
n/a |
Is FDA regulated |
No |
Health authority |
|
Study type |
Observational
|
Clinical Trial Summary
Colorectal cancer is one of the most common causes of cancer-related death. Early diagnosis
is extremely important in terms of treatment and mortality. In this study, we investigated
the diagnostic value of serum autotaxin levels in colorectal cancer.
Description:
Colorectal cancer (CRC) is the third most common type of cancer worldwide. Among the causes
of death due to cancer; it is the second most common among both genders with a rate of 9.2%
after lung cancer . Early detection of the disease is important for survival. National
screening programs attempt to detect this disease at an early stage.
Autotaxin (ATX) molecule is a member of the nucleotide pyrophosphatase/phosphodiesterase
enzyme family (ENNP), It is secreted at 125 kDa, has lysophospholipase D activity in the
lysophosphatidic acid (LPA) pathway, and is located at the 24th locus of the long arm of the
8th chromosome. This is also called ENPP2. It was discovered to be an autocrine
motility-stimulating factor released by human melanoma A-2058 cells . Lysophosphatidic acid
(LPA) is a lipid signalling molecule located in the cell membrane. LPA functions as an
autocrine/paracrine messenger through at least six G protein-coupled receptors (GPCR) known
as LPA 1-6. It plays physiologically important roles in various cellular processes, including
wound healing, differentiation, cell proliferation, and migration. The role of ATX in the
bioactivity of LPA is correlated with the lysophosphatidyl-D (lysoPLD) activity of ATX. ATX
molecule; With this enzyme activity, it plays a fundamental role in the conversion of
lysophosphatidylcholine to lysophosphatidic acid . Many studies have demonstrated the
biological effects of the autotaxin-lysophosphatidic acid (ATX-LPA) signalling pathway in
cancer. In vitro and in vivo studies have shown that increased ATX-LPA signalling contributes
to cancer initiation and progression. Current evidence supports the role of the ATX-LPA
signalling pathway in the proliferation, invasion, adhesion, and angiogenesis of cells, and
is effective in cancer development and metastasis. Increased ATX expression has been reported
in various cancers, such as glioblastoma, hepatocellular and thyroid carcinomas, breast,
pancreatic, colon, and hematological cancers .
The ATX molecule has the feature of being a molecule that will be effective in the future,
not only in the diagnosis of cancer, but also in the treatment process and to be studied
extensively. in this study, we aimed to examine the diagnostic and biological behaviour
relationship between serum ATX levels and colorectal cancer and to determine the cut-off
value for serum ATX levels in colorectal cancer.
Serum ATX levels were compared between the patient and control groups. ATX levels were
analysed in subgroups formed according to the demographic, clinical, pathological, and
laboratory characteristics of the patient group.